3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Glioma
3
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Temozolomide
128
Radiotherapy
85
Bevacizumab
43
Radiation
30
Carmustine
29
Irinotecan
22
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
Drug Therapy
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gene Expression Profiling
7
Gefitinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gliosarcoma
×
CLR1404
×
CNS
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled